Medication info
Dafogin 10 mg (Dapagliflozin)

Dafogin 10 mg (Dapagliflozin)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin›10mg / 1 tablet
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
Yellow, double convex, diamond-shaped film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP × 3]
Approval status
Active

MFDS item code 202002316 · Approved 2020.04.02 · Insurance code 647804980

Summary

Main use
Improvement of blood glucose in type 2 diabetes; treatment of chronic heart failure and chronic kidney disease
Who takes it
Adults · Children
Adult dose
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for both monotherapy and add-on combination therapy with other glucose-lowering agents, including insulin. When this medicine is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received pharmacological treatment for diabetes, the recommended initial dose of this medicine when used in combination with metformin is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - eGFR less than 25 mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, 5 mg is recommended as the starting dose. If well tolerated, this dose may be increased to 10mg. Older adults (≥ 65 years) Dosage adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
Child dose
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose in type 2 diabetes; treatment of chronic heart failure and chronic kidney disease

  • Type 2 diabetes
  • blood sugar control issues
  • cardiovascular diseases
  • cardiovascular risk factors
  • chronic heart failure
  • heart failure
  • chronic kidney disease
  • decreased glomerular filtration rate
  • end-stage kidney disease
  • increased risk of kidney-related mortality
View approved original text

This drug is used in conjunction with dietary and exercise therapies to help control blood sugar levels in patients with type 2 diabetes. It may also benefit patients with type 2 diabetes who have cardiovascular disease or risk factors. In patients with chronic heart failure, it is used in combination with other treatments to reduce the risk of death and hospitalization due to cardiovascular disease. For patients with chronic kidney disease, it is effective in reducing the risks associated with decreased kidney function and in lowering cardiovascular mortality rates, used alongside standard therapy. This drug is used to improve the health of patients with diabetes, heart failure, and kidney disease.

How to take

Adult dose

Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for both monotherapy and add-on combination therapy with other glucose-lowering agents, including insulin. When this medicine is used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received pharmacological treatment for diabetes, the recommended initial dose of this medicine when used in combination with metformin is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - eGFR less than 25 mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, 5 mg is recommended as the starting dose. If well tolerated, this dose may be increased to 10mg. Older adults (≥ 65 years) Dosage adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.

Child dose

The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Precautions

This drug must not be used in patients allergic to its active ingredient or excipients. It should also not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Additionally, the drug should not be given to patients with inherited lactose intolerance or galactose intolerance, or those with certain lactose-degrading enzyme deficiencies. Patients undergoing dialysis should not use this drug. Use with caution in patients with reduced fluid volume or poor kidney function. This drug may cause low blood pressure or worsen kidney function, and fluid status and kidney function should be carefully monitored before and after administration. In patients with moderate to severe kidney impairment, blood sugar control effects may be diminished, and it is not recommended for use in patients with very severe kidney dysfunction. During treatment with this drug, there may be a risk of genital infections or urinary tract infections, and patients should seek immediate treatment if infection symptoms develop. There is a risk of hypoglycemia, so dosage adjustments may be necessary when used with insulin or sulfonylureas. Be cautious of dehydration or hypotension symptoms due to reduced fluid volume, and consider temporarily stopping use if symptoms appear. Serious metabolic disturbances such as diabetic ketoacidosis may occur, so if symptoms such as nausea, vomiting, abdominal pain, or breathing difficulties occur, an immediate hospital visit is required. Women who are pregnant or nursing should avoid using this drug, and administration should be discontinued if pregnancy is confirmed. Elderly patients or those with reduced kidney function should be particularly cautious, and regular kidney function tests are necessary. This drug does not significantly affect driving or operating machinery, but caution is needed due to the potential for hypoglycemic symptoms. There is no specific antidote for overdose, and appropriate treatment should be given according to symptoms, and hospitalization may be necessary if needed. This drug has not been established for safety and efficacy in children, so it is not prescribed for pediatric use. Regular consultation with a physician is crucial during treatment, and any abnormal symptoms must be immediately reported.

Side effects

Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, reduced fluid volume, polydipsia, diabetic ketoacidosis, dizziness, constipation, dry mouth, back pain, dysuria, polyuria, nocturia, interstitial nephritis, urethritis, vulvar itching, genital itching, elevated hematocrit, decreased renal creatinine clearance at the beginning of treatment, dyslipidemia, elevated serum creatinine at the beginning of treatment, elevated blood urea, weight loss, acute pyelonephritis, rash, angioedema, urosepsis, pyelonephritis, acute kidney injury, renal dysfunction, gastroesophageal reflux disease, upper abdominal pain, diverticulosis, intestinal perforation, acute pancreatitis, chronic pancreatitis, hyperglycemia, sensory disturbances, cerebral infarction, nerve compression, weakness, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina, myocardial infarction, bile duct stones, cholangitis, alcoholic liver cirrhosis, depression, suicide attempt, gastric adenocarcinoma, anaphylactic reaction, sensory loss, headache, nasopharyngitis, upper respiratory tract infection, edema, fever, foreign body sensation, facial edema, facial pain, warmth, flu-like symptoms, breast mass, erectile dysfunction, benign prostatic hyperplasia, breast pain, genital rash, menorrhagia, genital edema, uterine bleeding, vaginal bleeding, vulvar discomfort, menstrual irregularity, itching, urticaria, cold sweats, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, ligament sprain, diabetic retinopathy, cough, dyspnea, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyp, tinnitus

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container to protect it from air and moisture. Additionally, it should be kept away from excessively hot or cold areas and stored at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow, double convex, diamond-shaped film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP × 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.